The Dynamic Roles of Visfatin and Obestatin Serum Concentration in Pancreatic Beta Cells Dysfunction (HOMA-beta) and Insulin Resistance (HOMA-IR) in Centrally Obese Men

Bayu Winata Putera, Cynthia Retna Sartika, Andi Wijaya


BACKGROUND: Obesity is a major health problem in the world today. Obesity is closely associated with insulin resistance and type 2 diabetes. Epidemiological studies have shown that obese persons are in a state of insulin resistance, however, most of them do not progress to type 2 diabetes. This occurs because the beta cell function is still good enough for maintaining normal glucose level. Obestatin and visfatin are cytokines that are known to have a role in beta cell function. The aim of this study was to assess the relationship between visfatin and obestatin and Homeostasis Model Assessment of beta cell function (HOMA-β) and Homeostasis Model Assessment of insulin resistance (HOMA-IR).

METHODS: This was a cross-sectional study involving 80 central obesity men with waist circumference >90 cm, age 30-65 years old. Visfatin and obestatin were measured by ELISA method. Beta pancreas cell dysfunction and insulin resistance were calculated by HOMA model.

RESULTS: Our study showed a correlation between visfatin and HOMA-β (r=0.244 and p = 0.029) and visfatin with HOMA-IR (r=0.287 and p=0.001) and no correlation was found between obestatin with HOMA-β (r=0.010 and p=0.990) and obestatin with HOMA-IR (r=0.080 and p=0.480). We also found visfatin and obestatin concentrations were fluctuative depending on the measurements of the waist circumferences.

CONCLUSIONS: High visfatin and low obestatin concentration were independently associated with increased beta pancreas cell dysfunction and insulin resistance.

KEYWORDS: obesity. visfatin, obestatin, beta cell dysfunction (HOMA-β), insulin resistance (HOMA-IR)

Full Text:



Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: The missing link between insulin resistance and obesity. Diabetes Metab. 2008; 34: 2-11, CrossRef.

Avram MM, Avram AS, James WD. Subcutaneous fat in normal and diseases state 3, adipogenesis: from stem cell to fat cell. J Am Acad Dermatol. 2007; 56: 472-92, CrossRef.

Sethi JK, Puig JV. Adipose tissue function and plasticity orchestrate nutritional adaption. J Lipid Res. 2007; 48: 1253-62, CrossRef.

Wallen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Invest. 2005; 115: 1111-9, CrossRef.

Engfeldt P, Arner P. Lipolysis in human adipocytes, effect of cell size, age and regional differences. Horm Metab Res Suppl. 1988; 19: 26-9, PMID.

Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RES. Enlarged subcutaneous abdominal adipocyte size but not obesity itself, predict type ll diabetes independent of insulin resistance. Diabetologia. 2000; 43: 1498-506, CrossRef.

Beltowski J. Apelin and visfatin: unique “beneficial” adipokines upregulated in obesity? Med Sci Monit. 2006; 12: RA112-9, PMID.

Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentration and fat depot-specific mRNA expression in humans. Diabetes. 2005; 54: 2911-6, CrossRef.

Sommer G, Kralisch S, Kloting N, Kamprad M, Schrock K, Kratzsch J, et al. Visfatin is a positive regulator of MCP-1 in human adipocytes in vifro and in mice in vivo. Obesity. 2010; 18: 1486-92, CrossRef.

Rocha VZ, Folco EJ. lnflamatory concept of obesity. Int J lnflam. 2011; 2011: 61-75, CrossRef.

Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: Many choices of menu. Genes Dev. 2007; 21: 1443-55, CrossRef.

Hassouna R, Zizzari P, Tolle V. The ghrelin/obestatin balance in physiological and pathological control of growth hormone secretion, body composition and food intake. J Neuroendocrinol 2010; 22: 793-804, CrossRef.

Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, et al. Obestatin promotes survival of pancreatic beta cells & human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 2008; 57: 967-79, CrossRef.

Ciampelli M, Leoni F, Cucinelli F, Mancuso S, Panunzi S, De Gaetano A, et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab. 2005; 90: 1398-406, CrossRef.

Matthews, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9, CrossRef.

Basir H, Aman AM, Adam FMS, Adam JMF. Insulin resistance and beta cell dysfunction in obese subject with dysglycemia. Medicinus. 2009; 22: 137-41, article.

Kaminska A, Kopczynska E, Bronisz A, Zmudzirlska M, Bielinski M, Borkowska A, et al. An evaluation of visfatin levels in obese subject. Endokrynol Pol. 2010; 61: 169-73, PMID.

Trayhurn P. Adipocyte biology. Obes Rev. 2007; 8 (Suppl 1): 41-4, CrossRef.

Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic B-cells death in type 1 and type 2 diabetes, many differences, few similarities. Diabetes. 2005; 54: S97-107, CrossRef.

Riesco M, Barcelo A, Vila M, Belmonte M, Ruiz O, Lopez-Escribano H, et al. Plasma levels of visfatin and obestatin in morbidly obese subject with and without type 2 diabetes mellitus. Obesity and Metabolism. 2009; 5: 9-12.

Lacquaniti A, Donato V, Chirico V, Buemi A, Buemi M. Obestatin: An interesting but controversial gut hormone. Ann Nutr Metab. 2011; 59: 193-9, CrossRef.


Indexed by:






The Prodia Education and Research Institute